Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...
Dr. Boris Naraev, a medical oncologist specializing in patient care for those suffering from gastrointestinal, neuroendocrine ...
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...
“These medicines will give people more treatment options and help them to live well for longer,” says Pharmac’s Director Equity and Engagement, Dr Nicola Ngawati. “We expect about 180 people will ...
Tragically, it claims the lives of 9,558 people annually, with over 70% succumbing within a year of being diagnosed. Just one ...
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
The standard treatment for grade 1 or 2 nonfunctional, unresectable gastroenteropancreatic neuroendocrine tumors is monotherapy ... less than 5% with diffuse liver metastases.
Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
Salk Institute researchers found that regulating bile acids—specifically reducing harmful ones and increasing UDCA—can enhance T cell function and potentially make immunotherapy more effective for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback